Back to GOLDMAN SACHS GROUP INC GOLDMAN SACHS GROUP INC

ACRVACRV
12 quarters

Position history for GOLDMAN SACHS GROUP INCGOLDMAN SACHS GROUP INC's holdings in ACRIVON THERAPEUTICS INC

Yes. Goldman Sachs holds 14,920 shares of ACRV (Acrivon Therapeutics), worth $26,558, as of its Q2 2026 13F filing. It increased the position by 178 shares (+1.2%) from Q1 2026. Goldman Sachs has held ACRV since Q2 2024, across 9 quarterly 13F filings.

Current Value

$26,558

Current Shares

14,920

Total Value Change

-$420,418

Total Shares Change

-23,880

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
14,920
+1.2%
$26,5580.0%$1.78
13
2026-Q1
Decreased
14,742
-87.7%
$20,4910.0%$1.39
0
2025-Q4
Increased
119,422
+504.9%
$287,8070.0%$2.41
26
2025-Q3
Decreased
19,742
-85.9%
$35,7330.0%$1.81
0
2025-Q2
Increased
140,055
+143.5%
$166,6650.0%$1.19
25
2025-Q1
Decreased
57,519
-75.8%
$116,7630.0%$2.03
0
2024-Q4
Increased
237,552
+19.9%
$1.4M0.0%$6.02
30
2024-Q3
Increased
198,168
+712.7%
$1.4M0.0%$7.00
41
2024-Q2
New
24,384
-
$141,4270.0%$5.80
34
2023-Q2
Exited
0
-100.0%
$00.0%$12.96
0
2023-Q1
Decreased
13,718
-64.6%
$174,0810.0%$12.69
0
2022-Q4
New
38,800
-
$446,9760.0%$11.52
33

Other major holders of ACRV: RA CAPITAL MANAGEMENT, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used